The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.

I Mazur, Natalie; Higgins, Deborah; C Nunes, Marta; A Melero, José; C Langedijk, Annefleur; Horsley, Nicole; J Buchholz, Ursula; J Openshaw, Peter; S McLellan, Jason; A Englund, Janet; Mejias, Asuncion; A Karron, Ruth; Af Simões, Eric; Knezevic, Ivana; Ramilo, Octavio; A Piedra, Pedro; Y Chu, Helen; R Falsey, Ann; Nair, Harish; Kragten-Tabatabaie, Leyla; Greenough, Anne; Baraldi, Eugenio; G Papadopoulos, Nikolaos; Vekemans, Johan; P Polack, Fernando; Powell, Mair; Satav, Ashish; E Walsh, Edward; T Stein, Renato; S Graham, Barney; J Bont, Louis; Syncytial Virus Network (ReSViNET) Foundation, Respiratory

doi:10.1016/s1473-3099(18)30292-5

Public

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.

Published in The Lancet. Infectious diseases • Oct 1, 2018

NobleIDark:/48914/w1/20260526/1914FE04Record on NobleID

Authors:

Natalie I Mazur

,

Deborah Higgins

,

Marta C Nunes

Abstract

The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by p...

Discussions